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Hard corona (HC) protein, i.e., proteins 
that are strongly associated with the sur-
face of nanomaterials in biological envi-
ronments, has drawn much attention in 
the field of nanomedicine.[1–3] HC profiles 
critically affect the nanomedicine stealth 
effect,[3] cellular uptake,[4] nanoparticle 
pathophysiology,[5] and mitigate nano-
material-induced cytotoxicity.[6] Carefully 
designed nanomedicine could orchestrate 
HC profiles that facilitate blood–brain 
barrier (BBB) translocation in vivo without 
using BBB-target ligands.[7] Investigation 
of HC on 3D nanoparticles is influenced 
by the surface charge/surface chemistry 
and the 3-factor interactions between 
the size, specific surface area (SSA, the 
surface area/mass ratio), and the curva-
ture, i.e., both curvature and SSA are size-
dependent factors for HC formation.[8] 2D 
nanomaterials, i.e., nanomaterials where 
the third dimension is almost negligible 
(≈1 nm per layer), have much greater SSA 
when compared to 3D nanomaterials. For 
2D nanomaterials, SSA is mass-dependent 
Hard corona (HC) protein, i.e., the environmental proteins of the biological  
medium that are bound to a nanosurface, is known to affect the biological 
fate of a nanomedicine. Due to the size, curvature, and specific surface 
area (SSA) 3-factor interactions inherited in the traditional 3D nanoparticle, 
HC-dependent bio–nano interactions are often poorly probed and 
interpreted. Here, the first HC-by-design case study in 2D is demonstrated 
that sequentially and linearly changes the HC quantity using functionalized 
graphene oxide (GO) nanosheets. The HC quantity and HC quality are 
analyzed using NanoDrop and label-free liquid chromatography–mass 
spectrometry (LC-MS) followed by principal component analysis (PCA). 
Cellular responses (uptake and cytotoxicity in J774 cell model) are 
compared using imaging cytometry and the modified lactate dehydrogenase 
assays, respectively. Cellular uptake linearly and solely correlates with 
HC quantity (R2 = 0.99634). The nanotoxicity, analyzed by retrospective 
design of experiment (DoE), is found to be dependent on the nanomaterial 
uptake (primary), HC composition (secondary), and nanomaterial exposure 
dose (tertiary). This unique 2D design eliminates the size–curvature–SSA 
multifactor interactions and can serve as a reliable screening platform to 
uncover HC-dependent bio–nano interactions to enable the next-generation 
quality-by-design (QbD) nanomedicines for better clinical translation.
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but not size-dependent; surface curvature is also not size- and 
SSA-dependent. It is, therefore, proposed as a better platform to 
clarify and uncover the HC-dependent bio–nano interactions. 
In this study, click-chemistry-modified 2D graphene oxide 
(GO) platform was used to examine the effect of NanoSAR 
(structure–activity relationship)[9] on HC and cytotoxicity, while 
avoiding the complex multigeometry interactions.[10] GO is 
being increasingly investigated in biomedical fields, e.g., drug 
delivery, bioimaging, tissue engineering, and biosensing.[11] It 
has been physically or chemically functionalized in numerous 
ways, e.g., click chemistry,[10] mechanochemistry,[12,13] mech-
ano-click-chemistry,[14] and is proposed as a nanoenabled 
drug delivery system (NanoDDS) due to its large SSA when 
compared to traditional liposomal 3D nanocarriers.[15] From 
molecular dynamics simulation studies, it is known that pro-
teins interact with GO via π–π stacking and hydrogen bonding 
(namely with aromatic tyrosine residuals and positively charged 
arginine and lysine residuals).[16] It is hypothesized that the 
introduction of hydrophobic functional groups, e.g., azide and 
alkyne to GO could create steric hindrance restricting the access 
of protein and water molecules to the oxygen derivatives on GO 
planar surface and edges, respectively. Sequential changes in 
GO surface properties were hypothesized to influence HC for-
mation and can be used as a screening tool to further explore 
the complex nature of the HC for nanomedicine.
GO was synthesized and characterized using Mei’s modi-
fied Hummers method, and further derivatized into clickable 
GOs, i.e., GON3, GO, and Click2 GO (C2GO) as previously 
reported.[10,12] The introduction of azide and alkyne were made 
through the azide-mediated nucleophilic epoxide ring-opening 
reaction and Steglich esterification of the carboxylic groups, 
respectively (Scheme 1).[17]
The film-like structure was confirmed for all materials using 
scanning transmission electron microscopy (STEM) and trans-
mission electron microscopy (TEM), regardless of the chemical 
functionalization (Figure S1, Supporting Information). GO, 
GON3, GO, and C2GO were washed (4×) with sterilized 
phosphate buffered saline (PBS) by centrifugation to afford 
washed pellets, which were resuspended and incubated with 
new-born calf serum (NCS) in vitro at 37 °C for 1 h to generate 
loosely bound and strongly bound soft corona (SC) and HC 
(see Figure S2 in the Supporting Information for workflow).[18]
SC and HC protein quantifications were performed using 
UV absorbance–based NanoDrop (Thermo Scientific) instead of 
bicinchoninic acid (BCA) assay due to the wider linear protein 
quantification ranges, better method reproducibility, and less 
day-to-day variability of the former (Figure S3A,B, Supporting 
Information). Overall protein recovery (total protein recovered 
from SC + HC + free post-incubation NCS) was 98+% for all 
tested samples, indicating a nearly complete HC desorption from 
the graphene, indirectly validating the use of this method for HC 
quantification (Figure S3C, Supporting Information). Variability 
in relative molar absorption coefficients was found to be less 
than 2% among the 4 HC samples (see the Supporting Informa-
tion for additional details on calculations), so normalization step 
was not required for NanoDrop protein concentration readings 
(Figure S4, Supporting Information). As shown in Figure 1A, 
SC displayed an ascending range of protein quantities at 
0.90 ± 0.05, 1.24 ± 0.06, 1.34 ± 0.11, and 1.52 ± 0.42 mg mg−1 
for GO, GON3, GO, and C2GO, respectively. The sequential 
functionalization with azide and alkyne via blocking the planar- 
and edge oxygen-bearing functional groups increased the con-
tent of SC. HC quantity was found to be 1.44 ± 0.06, 0.92 ± 0.07, 
1.06 ± 0.11, and 0.08 ± 0.38 mg mg−1 for GO, GON3, GO, 
and C2GO, respectively (Figure 1B). GO has the highest HC/
SC ratio and the highest HC+SC quantity. Azide- and/or alkyne 
modifications dramatically decreased the HC quantity, but the 
former repels HC more efficiently. C2GO showed a synergistic 
azide-and-alkyne effect in repelling HC.
Quantitative label-free liquid chromatography–mass spec-
trometry (LC-MS) was then used to identify and quantify the 
HC composition as reported before.[3] NCS was used as the con-
trol serum. HCs from the GO, GON3, GO, and C2GO were 
detached from the graphene using a buffer solution at 95 °C 
Adv. Mater. 2018, 30, 1802732
Scheme 1. GO surface chemistry modification with azide and alkyne.
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for 5–10 min (see Table S1 in the Supporting Information for 
formulation) and analyzed in technical duplicates. The profiling 
results obtained by LC-MS were expressed as relative protein 
abundance (RPA) in percentage, as shown in Figure 2A. The 
top 30 proteins with more than 0.5% total protein RPA in at 
least one of the HC samples were selected for further analysis. 
The protein recovery from the top 30 proteins was 99+% for 
all HC samples. Other HC proteins found with <0.5% total 
protein RPA were neglected for further analysis. Each of the 
selected 30 HC proteins was ranked within each HC sample 
by the RPA (relative protein abundance among the 30 pro-
teins), color-mapped and compared with the RPA of the control 
serum (see Table S2 in the Supporting Information for sum-
marized protein information). Each graphene–HC RPA profile 
was regarded as 30 variables and analyzed using multivariate 
analysis (MVA), i.e., principal component analysis (PCA). PCA 
Adv. Mater. 2018, 30, 1802732
Figure 1. Protein corona analysis for GO, GON3, GO, and C2GO. A) An ascending SC quantities per mg of graphene materials was found to 
be 0.90 ± 0.05, 1.24 ± 0.06, 1.34 ± 0.11, and 1.52 ± 0.42 mg mg−1 for GO, GON3, GO, and C2GO, respectively (Levene’s test p = 0.014, Welch’s 
F(3, 6.09) = 30.09, p < 0.001. Post hoc = Games–Howell, adjusted p = N.S. > 0.05, * < 0.05, ** <0.01, *** < 0.001). B) A declining HC quantity per mg 
of graphene materials, obtained by direct measurements of proteins detached by sodium dodecyl sulfate (SDS) was found to be 1.44 ± 0.06, 0.92 ± 
0.07, 1.06 ± 0.11, and 0.80 ± 0.38 mg mg−1 for GO, GON3, GO, and C2GO, respectively (Levene’s test p = 0.637. F(3, 8) = 174, p < 0.001. Post hoc 
= Tukey, adjusted p-value = N.S. > 0.05, * < 0.05, ** < 0.01, *** < 0.001).
Figure 2. Relative protein abundance (RPA) profiling by LC-MS. A) The hard corona compositions analyzed by LC-MS were expressed as relative hard 
corona protein abundance in percentages for the individual groups. Each protein was ranked by the RPA and color-mapped for the serum, HC–GO, 
HC–GON3, HC–GO, and HC–C2GO. B) Principal component analysis (PCA) for RPA of serum and graphene RPA. The RPA values in (A) were 
analyzed by PCA. B1) The Eigenvectors of the PC-1a and PC-2a. B2) PCA score plot shows that the graphene RPA is separated from the serum RPA 
by the principal component 1 (PC-1a), i.e., graphene RPA is different from the control serum. The graphene RPAs are separated by PC-2a. C). PCA for 
graphene RPA. C1) The Eigenvectors of the PC-1b and PC-2b. C2) PCA score plot of the graphene RPA shows separation between the clickable graphene 
(GON3, GO, and C2GO) and GO by PC-1b scores. A separation between the monoclickable derivatives (GON3, GO) and the double-clickable 
derivative (C2GO) is seen by PC-2b scores.
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reduces the data into a smaller number of artificial variables 
known as the principal components (PC), that is, the linear 
combinations of the original variables (30 protein RPA per 
graphene type). The PC that accounts for (explained) the most, 
and the second most variances in the data (i.e., most of the data 
variances are happening along the PC coordinate) is known as 
the first PC (PC-1) and the second PC (PC-2), respectively.[19]
Two PC analyses were performed. First, RPA% of the control 
serum and the graphene–HCs was first analyzed to see if the 
serum RPA% is significantly different from the graphene–
HC RPA%, i.e., to verify if graphene–HC RPA% is uniquely 
different from the serum. Second, the 4 graphene–HC RPA% 
were compared with each other to verify if the HC profile is 
significantly different. In brief, each HC profiling RPA% data 
can be considered as a vector in 30D space (each sample has 
30 RPA measurements). Dimensionality reduction was per-
formed by Eigenanalysis of the correlation matrix (where the 
variables are standardized; otherwise the proteins with small 
RPA would not contribute much to the analysis). The Eigen-
values (the fold changes/stretches of the Eigenvectors after 
linear transformation, i.e., the vector scalar) and the Eigenvec-
tors of each PCs were obtained. Eigenvalues are shown in the 
PC screening plots (Figure S5A1, Supporting Information), 
to identify the number of the PCs needed to explain most of 
the variance in the data. The higher the PC Eigenvalue, the 
more variances are explained; for the first PCA analysis, since 
the PC-1a and PC-2a combined would cover +80% of the total 
Eigenvalues combined, the 30D vector can be dimension-
ally reduced into a 2D subspace while still capturing +80% of 
the variance in the data, i.e., the critical data information was 
maintained. The loading plot provides additional visual inter-
pretation of the PC correlation by plotting the Eigenvectors of 
each variable for PC-1a and PC-2a (Figure 2B1 and Figure S5A2 
(Supporting Information)). The PC-1a and PC-2a scores (shown 
in Figure 2B2) are the linear combinations of the original 
data. The larger the absolute value of the variable Eigenvector 
(either positive or negative), the greater importance of the cor-
responding variables (proteins) in calculating the PCs. Positive 
and negative Eigenvectors contribute to positive and negative 
PC scores, respectively. From Figure 2B2, a clear separation 
between serum-RPA profile and graphene-RPA profile based 
on PC-1a can be seen, i.e., there is a definite difference in the 
protein composition for the control serum and all the gra-
phene–HC. Proteins with positive PC-1a Eigenvector values 
(24 out of 30 proteins tested) were found to have higher RPA 
on graphene derivatives, i.e., to have higher graphene binding 
affinity resulting in uniquely different graphene–HC profiles 
that are significantly different from the background serum 
protein profile (Figure 2B2, x-axis).
The second PCA for graphene–HC RPA% was analyzed 
similarly. The loading and screen plots are represented in 
Figure S5B (Supporting Information). The Eigenvectors of 
the PC-1b and PC-2b are shown in Figure 2C1. In the PCA 
score plot (Figure 2C2), all 4 graphene–HC are separated from 
each other, i.e., being significantly different. Positive PC-1b 
scores (attributed by proteins with positive PC-1b Eigenvectors 
preferentially bind GON3, GO, and C2GO) were found in 
GON3, GO, and C2GO, when compared to negatively scored 
GO (Figure 2C2, x-axis), i.e., the click chemistry–enabled GO 
displayed a different HC profile when compared to GO. In 
addition, the azide and alkyne double functionalized C2GO was 
well-separated from the monofunctionalized GON3 and GO 
by PC-2b scores.
To translate PCA results from artificial PC units (PC 
scores) into more readily interpretable biological functions, 
and to verify how PC scores are related to bio–nano interac-
tions, correlation studies were performed. The first correlation 
study was quantitative cellular uptake using J774 cells (mouse 
monocyte macrophage) incubated with all four GO deriva-
tives at 20 µg mL−1 concentration for 24 h (see “Methods” and 
Figure S6 in the Supporting Information for methods and 
sample preparation). Cellular uptake was evaluated with an 
imaging cytometer,[20] which imaged cells individually before 
and after graphene treatments (Figure 3A). Changes in the cell 
image bright-field light intensity (BFI) were normalized to the 
cell area. The lower the BFI, the higher the GO uptake, i.e., J774 
uptake: C2GO > GON3 > GO > GO (Figure 3B). The BFI 
of untreated J774 cells was then subtracted from the graphene 
groups; the resulting net BFI changes and HC/graphene w/w 
values were plotted as a function of the PC-1b scores and PC-2b 
scores to obtain correlation plots (Figure 3C,D). PC1b scores 
were found to be linearly correlated with both HC/graphene 
and BFI with R2 = 0.99626 and 0.98536, respectively; no 
correlation was found for PC-2b scores. A direct linear relation-
ship (R2 = 0.99634) was also found between the HC quantity 
and the changes in the BFI. The higher the HC quantity, the 
lower the cellular uptake, and the PC-1b score, i.e., the PC-1b 
score accurately represented, and can be translated into the HC 
quantity and cellular uptake level.
As the PC-2b score is not related to HC quantity and cellular 
uptake, the translation of PC-2b scores continued and hypoth-
esized to be associated with another critical aspect of bio–nano 
interactions: cytotoxicity/cell viability. A correlation study 
between the PCs and cell viability was performed by treating 
J774 cells with GO derivatives at 10, 50, 100 µg mL−1 for 
72 h (37 °C, 5% CO2). The 72 h cell viability results showed 
significant dose-dependent toxicity for all four GO derivatives 
(Figure 4A). The material-dependent cell viability was found 
in the following order: GO > GON3 > GO > C2GO. Super-
oxide dismutase (SOD) activity assay was performed for the 
viable cells after graphene treatment to verify if the cytotoxicity 
is related to oxidative stress. The SOD activity in viable J774 
cells decreased sequentially similar to the viability trend, i.e., 
GO > GON3 > GO > C2GO, implying an increased oxidative 
stress from GO to C2GO (Figure S7, Supporting Information). 
However, the SOD assay is not an ideal indicator for modeling 
bio–nano interactions due to the inherent data selection bias, 
i.e., only viable cells are analyzed. Lactate dehydrogenase (LDH) 
assay, which analyzes cell viability by taking into account the 
cell population as a whole (living and dead cells), was selected 
for further correlation analysis.
The cell viability trend, i.e., C2GO < GO < GON3 < GO, is 
partially different from the order found in cellular uptake studies: 
C2GO > GON3 > GO > GO. GON3 was taken up more than 
GO but appeared to be less toxic, i.e., the cellular uptake/HC 
quantity (PC-1b scores) does not translate directly into cytotox-
icity results, other factors were involved. Linear regressions were 
performed between the PC-1b scores, cell viabilities, and relative 
Adv. Mater. 2018, 30, 1802732
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Figure 3. Cellular uptake assessments. A) Cellular uptake of the graphene derivatives in J774 cells analyzed by imaging cytometer. Representative images of 
the J774 cells ± graphene imaged from the bright-field and dark-field channels are shown (scale bar = 20 µm). B) The cellular uptake results were expressed 
as bright-field (light) intensity per cell area with darker cells having reduced bright-field intensity indicating higher uptake. C) Correlation analysis for the 
bright-field intensity/cell area, and function of HC quantity as functions of PC-1b scores. Linear relationships were found between PC-1b scores and HC 
quantity, and between PC-1b scores and cellular uptake, with a R2 = 0.99626 and 0.98536, respectively. The lowest HC quantity was found to result in the 
highest cellular uptake. D) Correlation analysis for the bright-field intensity/cell area, and HC quantity as functions of PC-2b scores. No meaningful correla-
tion was found. E) Correlation analysis for the bright-field intensity/cell area as a function of HC quantity found a linear relationship with a R2 = 0.99634.
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SOD activities across three different dose ranges (10, 50, and 
100 µg mL−1). The resulting R2 ranged between 0.87 and 0.93 
(viability%, Figure 4B1), i.e., for overall cell viability, only ≈87–93 
of the variances were explained by the PC-1b scores, respectively. 
PC-1b scores are particularly poor in describing the cell viability 
(R2 < 0.45) specifically for cells treated with click-modified gra-
phene (GON3, GO, C2GO, Figure 4B2). A much better cor-
relation (linearity) was found when cell viability (R2 = 0.96–0.99) 
(Figure 4B3) was plotted as functions of PC-2b scores across 
all dosing ranges. PC-2b scores could explain +96% of the vari-
ance seen among the click-modified derivatives, suggesting that 
PC-2b scores are well translated into cytotoxicity.
To better understand and visualize how overall cell viability 
is influenced by HC quantity/quality-dependent and dose-
dependent factors (factor A: PC-1b scores; factor B: PC-2b 
scores, factor C: graphene dose in µg mL−1), a retrospective 
analysis using historical cell viability data (Figure 4A) was 
performed.[21] Response surfaces and the predictive equa-
tions were then established. Raw data used to create the pre-
dictive response surface (cell viability%) are summarized in 
Table S3 (Supporting Information). Data were analyzed using 
Design-Expert 9, v9.0.6.2 (Stat-ease, Inc., USA). A suitable 
predictive model was achieved using sequential model sum 
of squares (SMSS, Tables S4–S8, Supporting Information). A 
Adv. Mater. 2018, 30, 1802732
Figure 4. Cytotoxicity assessments. A) The modified lactate dehydrogenase (mLDH) assay. mLDH was used to evaluate the cell viability of GO, 
GO, GON3, GO, and C2GO at 10/50/100 µg mL−1 after 72 h incubation (37 °C, 5% CO2). In J774 cells (mouse monocyte macrophage cells), 
significant dose- and material-dependent toxicities were found in J774 (for 10 µg mL−1: Welch’s F(5, 30.8461) = 2788.81, p < 0.001; 50 µg mL−1: Welch’s 
F(5, 31.9966) = 2608.28; 100 µg mL−1: Welch’s F(5, 34.4422) = 2657.15, p < 0.001. Post hoc = Games–Howell, adjusted p = N.S. > 0.05, * < 0.05, ** 
< 0.01, *** < 0.001). B1–B3) Linear correlation studies between PC-1b score, PC-2b scores, and cell viability (%). C) Response surface of cell viability 
(dose = 55 µg mL−1, 72 h) as a function of both PC-1b and PC-2b scores.
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detailed description of the retrospective design of experiment 
(DoE) analysis is provided in the Supporting Information. The 
final fitted equation in terms of coded factors (so that factors of 
different units can be compared) is listed as the following
A B Clog Viability% 1.30 0.36 0.23 0.1810 ( ) = − + −  (1)
From Equation (1), cell viability was a collective consequence 
of all three factors, where the factor A (PC-1b score) has the 
largest effect (largest absolute coefficient = 0.36) followed by 
factor B (PC-2b score, absolute coefficient = 0.23; (0.23/0.36) × 
100% = 64%, i.e., the influence of factor B is ≈64% of factor A), 
and factor C (graphene dose, absolute coefficient = 0.18; 
(0.18/0.36) × 100% = 50%, i.e., factor C is half as influential 
as factor A). These results suggest that the overall cell viability 
was mainly correlated with cellular uptake/HC quantity (low 
uptake GO vs high uptake C2GO). At higher uptake levels, e.g., 
GON3 versus GO versus C2GO, proteins that orchestrated 
the HC (HC quality) are the dominating factors for cytotoxicity, 
despite questions remained for the exact mechanism of intra-
cellular HC-induced cytotoxicity. Finally, the overall cytotoxicity 
is also dose-dependent with a lesser influence when compared 
to PC-1b and PC-2b scores (as reflected by the coefficient values 
of coded factors). The final fitted equations and response sur-
face in terms of actual factor (actor factor units) is shown in 
Equation (2) and Figure 4C.
log Viability% 1.42 0.08 PC1b
0.06 PC2b 0.004 Dose
10 ( ) = − ×
+ × − ×
 (2)
The more negative the PC-2b score is, the less viable the 
treated cells are (Figure 4B3,C). As the PC-2b score is contrib-
uted by all 30 proteins, negative scores are collectively summed 
by HC proteins with negative Eigenvectors. HC proteins with a 
larger negative PC-2b Eigenvector (e.g., vitamin D binding pro-
tein (DBP), intra-alpha-trypsin inhibitor heavy chain H2, beta-2 
glycoprotein 1, and POTE Ankyrin domain family member F, 
Figure 2C1) are correlated with lower cell viability and higher 
oxidative stress. These proteins were more abundant in HC of 
C2GO (the most toxic derivative in vitro), except POTE Ankyrin 
domain family member F, where the RPA in GO > C2GO > 
GON3 > GO. The high RPA of POTE Ankyrin domain family 
member F in GO also explained the overall negative PC-2b 
score for GO. Proteins with larger positive PC-2b Eigenvectors 
(e.g., hemoglobin beta/delta, prothrombin, antithrombin-III, 
complement C9, Apo A-I, Apo C-III, gelsolin, and lactotrans-
ferrin) contributed more to positive PC-2b scores and translated 
to higher cell viability and lower oxidative stress. GON3 which 
demonstrated the highest biocompatibility among the deriva-
tives also showed the highest RPA for hemoglobin beta/delta, 
Apo C-III, complement C9, prothrombin, antithrombin-III, and 
gelsolin, while having the lowest RPA for DBP.
Designing the HC in 2D provides a simplified platform 
allowing NanoSAR studies with fewer interferences. As hypoth-
esized, the surface modifications blocked proteins binding 
presumably by steric hindrance as implied by the sequentially 
changing SC and HC, respectively (Figure 1A,B). Despite 
many studies attempted to modify 3D nanoparticles by deco-
rating nanoparticles with different polymers and different 
chain lengths, only categorical HC-quality changes (e.g., pref-
erentially absorb or repel certain HC proteins), material-based 
sequential HC-quantity changes (i.e., the same base material 
with various levels of HC quantity) were difficult to achieve.[3,22] 
There are previously reported HC studies on 2D graphene, 
which the change in HC quantity was achieved by changing the 
serum content in cell culture media with little control over the 
2D surface;[6] such approach introduced additional systematic 
errors and led to difficulties to interpret NanoSAR findings.[23] 
Furthermore, the mitigation effect was mostly concluded for 
GO by qualitative TEM ultrastructural studies without further 
quantitative analysis.[6] To the best of our knowledge, this is the 
first study demonstrating the sequential changes of HC quan-
tity and quality for potential NanoDDS, which also clarified the 
NanoSAR by quantitative NanoDrop–LC-MS/PCA (Figures 1 
and 2). Correlation studies were performed to decode PC-1b and 
PC-2b scores, which were translated into HC quantity/cellular 
uptake (linearity R2 > 0.98, Figure 3), and cytotoxicity (modi-
fied lactate dehydrogenase assay activity linearity R2 > 0.96, 
Figure 4B3), respectively. Cellular uptake is almost completely 
HC-quantity-dependent. Cytotoxicity, however, is collectively 
affected by HC quantity, HC quality, and graphene exposure 
dose (Equations (1) and (2)), Figure 4C). For example, GO 
scored similarly to that of GO in PC-2b, which should have 
translated into similar cytotoxicity. However, GO is signifi-
cantly more toxic to cells due to a much higher cellular uptake.
Intrinsic sequence-based protein properties, e.g., molecular 
weight, intrinsic solubility, and isoelectric charges,[24] were used 
in attempting to correlate protein properties with PCA scores 
(and biological translations) with no success (Table S2 and 
Figures S8–S14, Supporting Information). Structure-based pro-
tein PCA could be involved in future studies as protein func-
tions are better described or predicted by sequence motif–based 
or structure-based methods, as demonstrated in other studies.[25] 
Questions remained to the mechanistic understanding of why 
any given HC protein is biocompatible or toxic, as the intracel-
lular fate of the nanomaterial and the associated HC could also 
be different.[1] The usefulness of the 2D GO high-throughput 
platforms provides an easy way to screen multiple serum pro-
teins for future single-(HC)-protein NanoSAR studies.
The first protein corona-by-design example in 2D was dem-
onstrated to investigate the effects of HC-dependent bio–nano 
interactions. The click-modified 2D GO platform successfully 
creates material-dependent sequential changes in both HC 
quantity and HC quality while eliminating the size–curva-
ture–SSA multifactor interactions. HC quantity influenced the 
degree of cellular uptake; while HC quantity (primary), HC 
quality (secondary), and material exposure dose (tertiary) influ-
enced the cytotoxicity collectively. This study provides a 2D pro-
tein corona quality-by-design (QbD) platform with an accurate 
prediction of bio–nano interaction. Identifying “safe” and “toxic” 
protein corona profiles in 2D could pave the way for future QbD 
2D/3D nanomedicines and better clinical translation.
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